Cassidy Bio

Cassidy Bio addresses a fundamental bottleneck in therapeutic gene editing: the design and validation of safe, effective, and scalable CRISPR guide RNAs and editing interventions remain labor-intensive, empirical, and largely driven by trial-and-error experimentation. Traditional gene therapy development relies on small-scale wet-lab validation cycles, manual protocol optimization, and incomplete predictive models for clinical efficacy and off-target effects. These constraints have limited the pace of therapeutic advancement and increased development risk, particularly for complex genomic contexts where guide-RNA specificity and delivery efficiency vary significantly across patient populations and genetic backgrounds.

Cassidy Bio's core innovation is a genomic foundation model—a large-scale machine-learning system trained on proprietary wet-lab validation data combined with population-scale genomics from Israeli biobanks and international datasets—to predict optimal guide-RNA design, estimate off-target risk, and recommend delivery strategies with improved clinical relevance. This approach leverages Israel's exceptional biobank resources, which link decades of electronic health records with comprehensive whole-genome sequencing from diverse patient populations, creating a rich training dataset that is both clinically grounded and representative of real therapeutic deployment contexts.

The company was founded in 2024 by Rom Kshuk (co-founder), Ayal Hendel (co-founder, CRISPR scientist), and Yaniv Shmueli (co-founder, AI researcher). The founding team combines deep expertise in CRISPR molecular biology, computational genomics, and machine learning, with advisory support from recognized leaders in gene therapy including Dr. Vic Myer (former Chief Technology Officer at Editas Medicine), Dr. Saar Gill (University of Pennsylvania immunotherapy researcher), and scientists from Ultima Genomics and Intellia Therapeutics. This credibility within the global CRISPR community reflects both the technical depth of the approach and the strategic relevance of solving guide-RNA design at scale.

Cassidy Bio emerged from stealth in November 2025 and closed an $8 million seed funding round led by Ahren Innovation Capital, with participation from Lool Ventures, 10D VC, and venture-seeding support from AstraZeneca and Merck KGaA through the AION Labs initiative. The funding reflects confidence from both specialized biotech VCs and major pharmaceutical companies that AI-driven gene therapy design is a credible and timely market opportunity. The AION Labs participation is particularly significant, as it signals that established pharma sees Cassidy Bio's platform as potentially relevant to their own therapeutic pipelines and internal CRISPR programs.

The market opportunity is substantial. The global CRISPR therapeutics market is estimated at $2-5 billion annually and growing at 15-25% CAGR through 2030, driven by expanding approved therapies (Sickle Cell, Beta-Thalassemia) and growing adoption in oncology, immune-mediated disease, and genetic disorders. However, the industry's current bottleneck is not CRISPR molecular viability—the technology works—but rather the time and cost to design, validate, and clinically optimize therapies for specific patient populations and genomic contexts. Traditional approaches require 3-7 years and $200-400 million per program; AI-first approaches like Cassidy Bio's platform aim to reduce timelines by 30-50% and accelerate the pace of therapeutic discovery. This efficiency gain is valuable to both incumbent pharma (seeking to diversify late-stage pipelines) and emerging gene-therapy companies (seeking to differentiate in a competitive space).

Competitive landscape includes both direct gene-therapy design tools and broader AI-driven drug discovery platforms. Direct competitors include Genentech (using internal AI for CRISPR program design), Enable Medicine (computational biology platform for cellular engineering), and Modifi Bio (guide-RNA optimization). Broader competitive context includes large AI-in-biotech platforms (Deep Genomics, Atomwise, Insitro) that address design problems across modalities. Cassidy Bio's differentiation is specificity: the platform is purpose-built for CRISPR guide-RNA design and leverages Israeli biobank data as a moat, creating a feedback loop where clinical validation of therapies improves the model and compounds the advantage. The platform's claims of improved specificity and clinical prediction are not yet publicly validated through peer review or published clinical trials, requiring careful diligence on actual predictive accuracy and off-target mitigation claims.

From a dual-use and strategic perspective, Cassidy Bio's technology is primarily commercial and therapeutic rather than defense-oriented. However, the platform's capabilities in genomic analysis and predictive biology create adjacency to biosecurity and defensive biotech contexts: capability in rapid, accurate CRISPR design could be adapted to identify or predict genetic vulnerabilities in pathogens or support defensive biotech research. This is not the company's primary thesis, but it is worth noting for strategic readers evaluating Israeli biotech innovation and its potential cross-application to security or resilience contexts. The more direct strategic relevance is in advancing Israeli biotechnology leadership and supporting the growth of a thriving gene-therapy ecosystem that attracts global pharma partnerships and licensing opportunities.